Home The Word Brain My Amedeo FAQ Privacy About   


Amedeo C49

English + 你好 (nǐ hǎo) = limitless possibilities.
Start learning Mandarin Chinese today—for free, forever.

Amedeo C49 is completely free, for life. Next week: +49.


  Breast Cancer

  Free Subscription


Articles published in Oncogene

Retrieve available abstracts of 70 articles:
HTML format



Single Articles


    September 2025
  1. CAI Y, Du J, Wang H, Shen L, et al
    KPNA2 silencing sensitizes triple-negative breast cancer to chemotherapy by promoting multipolar division and suppressing DNA damage repair.
    Oncogene. 2025 Sep 18. doi: 10.1038/s41388-025-03503.
    PubMed     Abstract available


  2. CHEN H, Zhou Y, Zhang Y, Fan Y, et al
    TRIM21-mediated ubiquitination of SIX2 attenuates breast cancer stemness via LGSN suppression.
    Oncogene. 2025 Sep 15. doi: 10.1038/s41388-025-03572.
    PubMed     Abstract available


  3. DONG X, Dai H, Yao L, Lin Y, et al
    EMC2 promotes triple negative breast cancer growth by protecting FDFT1 from endoplasmic reticulum associated degradation to impair ferroptosis susceptibility.
    Oncogene. 2025 Sep 10. doi: 10.1038/s41388-025-03545.
    PubMed     Abstract available


  4. UMBRICHT CB, Evron E, Gabrielson E, Ferguson AT, et al
    Correction: Hypermethylation of 14-3-3 sigma (stratifin) is an early event in breast cancer.
    Oncogene. 2025 Sep 5. doi: 10.1038/s41388-025-03555.
    PubMed    


  5. TIAN L, Jiao X, Wang C, Li D, et al
    PPARgamma acetylation governs mammary adenocarcinoma tumor growth via acetylated residues that determine DNA sequence-specific binding.
    Oncogene. 2025;44:3476-3492.
    PubMed     Abstract available


    August 2025
  6. CHEN X, Ma C, Li Y, Liang Y, et al
    Correction: COL5A1 promotes triple-negative breast cancer progression by activating tumor cell-macrophage crosstalk.
    Oncogene. 2025 Aug 28. doi: 10.1038/s41388-025-03554.
    PubMed    


  7. BARNIEH FM, Morton J, Olanrewaju O, El-Khamisy SF, et al
    Decoding the adaptive survival mechanisms of breast cancer dormancy.
    Oncogene. 2025 Aug 27. doi: 10.1038/s41388-025-03529.
    PubMed     Abstract available


  8. MIYAN J, Kumar N, Moinuddin, Malik SA, et al
    Leveraging RAS-mSIN1 interaction to selectively inhibit mTORC2 employing competitive RAS binding peptide: implications in breast cancer metastasis.
    Oncogene. 2025 Aug 23. doi: 10.1038/s41388-025-03516.
    PubMed     Abstract available


  9. HAWES ML, Moody MA, McCauley CR, Huddleston AG, et al
    Oncogenic effects of ECM remodeling in obesity and breast cancer.
    Oncogene. 2025 Aug 22. doi: 10.1038/s41388-025-03521.
    PubMed     Abstract available


  10. GITHAKA JM, Kirschenman R, Patel N, Tripathi N, et al
    Multiple anti-tumor programs are activated by blocking BAD phosphorylation.
    Oncogene. 2025;44:2530-2546.
    PubMed     Abstract available


  11. LIU J, Zhang S, Cao L, Zhang N, et al
    The deubiquitination-PARylation positive feedback loop of the USP10-PARP1 axis promotes DNA damage repair and affects therapeutic efficacy of PARP1 inhibitor.
    Oncogene. 2025;44:2515-2529.
    PubMed     Abstract available


    July 2025
  12. GUO L, Rao Y, Song Y, Hu J, et al
    SIX1 transmits signals for breast cancer progression via the ZEB1/IL6/STAT3 signaling axis.
    Oncogene. 2025 Jul 26. doi: 10.1038/s41388-025-03499.
    PubMed     Abstract available


  13. ZHAO Y, Qiao S, Hou X, Tian H, et al
    Correction: Bioengineered tumor microenvironments with naked mole rats high-molecular-weight hyaluronan induces apoptosis in breast cancer cells.
    Oncogene. 2025 Jul 24. doi: 10.1038/s41388-025-03506.
    PubMed    


  14. DURAN CL, Surve CR, Ye X, Chen X, et al
    Targeting CSF-1 signaling between tumor cells and macrophages at TMEM doorways inhibits breast cancer dissemination.
    Oncogene. 2025 Jul 11. doi: 10.1038/s41388-025-03485.
    PubMed     Abstract available


  15. WU W, Wu W, Xie X, Li J, et al
    DNMT1 is required for efficient DSB repair and maintenance of replication fork stability, and its loss reverses resistance to PARP inhibitors in cancer cells.
    Oncogene. 2025;44:2283-2302.
    PubMed     Abstract available


    June 2025
  16. LIU F, Liu W, Tan Y, Shang Y, et al
    PTEN neddylation aggravates CDK4/6 inhibitor resistance in breast cancer.
    Oncogene. 2025 Jun 18. doi: 10.1038/s41388-025-03468.
    PubMed     Abstract available


    May 2025
  17. ANAND V, El-Dana F, Baran N, Borgman J, et al
    GD3 synthase drives resistance to p53-induced apoptosis in breast cancer by modulating mitochondrial function.
    Oncogene. 2025 May 17. doi: 10.1038/s41388-025-03432.
    PubMed     Abstract available


    April 2025
  18. NING W, Yang J, Ni R, Yin Q, et al
    Correction: Hypoxia induced cellular and exosomal RPPH1 promotes breast cancer angiogenesis and metastasis through stabilizing the IGF2BP2/FGFR2 axis.
    Oncogene. 2025 Apr 22. doi: 10.1038/s41388-025-03422.
    PubMed    


  19. CHEN W, Jiang M, Zou X, Chen Z, et al
    Fibroblast Activation Protein (FAP)(+) cancer-associated fibroblasts induce macrophage M2-like polarization via the Fibronectin 1-Integrin alpha5beta1 axis in breast cancer.
    Oncogene. 2025 Apr 22. doi: 10.1038/s41388-025-03359.
    PubMed     Abstract available


  20. GAO Y, Li B, Jin Y, Cheng J, et al
    Spatial multi-omics profiling of breast cancer oligo-recurrent lung metastasis.
    Oncogene. 2025 Apr 15. doi: 10.1038/s41388-025-03388.
    PubMed     Abstract available


  21. CHEN S, Tang M, Yu X, Qian W, et al
    A microprotein encoded by LINC00263 promotes breast cancer osteolytic bone metastasis by inducing osteoclastogenesis and inhibiting osteoclast ferroptosis.
    Oncogene. 2025 Apr 12. doi: 10.1038/s41388-025-03400.
    PubMed     Abstract available


  22. PRADEEP C-, Zeisel A, Kostler WJ, Lauriola M, et al
    Correction: Modeling invasive breast cancer: growth factors propel progression of HER2-positive premalignant lesions.
    Oncogene. 2025 Apr 11. doi: 10.1038/s41388-025-03362.
    PubMed    


  23. GUO Z, Dong RW, Wu Y, Dong S, et al
    Cyclin-dependent kinase 4 and 6 inhibitors in breast cancer treatment.
    Oncogene. 2025 Apr 8. doi: 10.1038/s41388-025-03378.
    PubMed     Abstract available


  24. MAN KF, Darweesh O, Hong J, Thompson A, et al
    Correction: CREB1-BCL2 drives mitochondrial resilience in RAS GAP-dependent breast cancer chemoresistance.
    Oncogene. 2025 Apr 2. doi: 10.1038/s41388-025-03369.
    PubMed    


  25. HUANG J, Luo S, Shen J, Lee M, et al
    Cellular polarity pilots breast cancer progression and immunosuppression.
    Oncogene. 2025;44:783-793.
    PubMed     Abstract available


  26. RANINGA PV, Zeng B, Moi D, Trethowan E, et al
    CBL0137 and NKG2A blockade: a novel immuno-oncology combination therapy for Myc-overexpressing triple-negative breast cancers.
    Oncogene. 2025;44:893-908.
    PubMed     Abstract available


  27. KIM K, Chadalapaka G, Lee S-, Yamada D, et al
    Editorial Expression of Concern: Identification of oncogenic microRNA-17-92/ZBTB4/specificity protein axis in breast cancer.
    Oncogene. 2025 Apr 1. doi: 10.1038/s41388-025-03363.
    PubMed    


  28. JAIN A, Barge A, Parris CN
    Correction: Combination strategies with PARP inhibitors in BRCA-mutated triple-negative breast cancer: overcoming resistance mechanisms.
    Oncogene. 2025 Apr 1. doi: 10.1038/s41388-025-03364.
    PubMed    


  29. MUGISHA S, Baba SA, Labhsetwar S, Dave D, et al
    S100A8/A9 innate immune signaling as a distinct mechanism driving progression of smoking-related breast cancers.
    Oncogene. 2025;44:1051-1062.
    PubMed     Abstract available


    March 2025
  30. WANG H, Wang H, Wang R, Li Y, et al
    Discovery of a molecular glue for EGFR degradation.
    Oncogene. 2025;44:545-556.
    PubMed     Abstract available


  31. ZHANG Z, Li F, Dai X, Deng J, et al
    A novel micropeptide miPEP205 suppresses the growth and metastasis of TNBC.
    Oncogene. 2025;44:513-529.
    PubMed     Abstract available


  32. JI L, Chen J, He L, Zhang F, et al
    Reversal of endocrine resistance via N6AMT1-NEDD4L pathway-mediated p110alpha degradation.
    Oncogene. 2025;44:530-544.
    PubMed     Abstract available


    February 2025
  33. WITKIEWICZ AK, Wang J, Schultz E, O'Connor TN, et al
    Using prognostic signatures and machine learning to identify core features associated with response to CDK4/6 inhibitor-based therapy in metastatic breast cancer.
    Oncogene. 2025 Feb 26. doi: 10.1038/s41388-025-03308.
    PubMed     Abstract available


  34. KONG Y, Lan T, Wang L, Gong C, et al
    Correction: BRD4-specific PROTAC inhibits basal-like breast cancer partially through downregulating KLF5 expression.
    Oncogene. 2025 Feb 3. doi: 10.1038/s41388-024-03250.
    PubMed    


  35. GAO ZX, Li CL, Zhang H, Zhang GH, et al
    LINC00882, transcriptionally activated by CEBP-beta and post-transcriptionally stabilized by METTL14-mediated m(6)A modification, exerts tumorigenesis by promoting PABPC1-mediated stabilization of ELK3 mRNA.
    Oncogene. 2025;44:363-377.
    PubMed     Abstract available


    January 2025
  36. MAN KF, Darweesh O, Hong J, Thompson A, et al
    CREB1-BCL2 drives mitochondrial resilience in RAS GAP-dependent breast cancer chemoresistance.
    Oncogene. 2025 Jan 31. doi: 10.1038/s41388-025-03284.
    PubMed     Abstract available


    December 2024
  37. GILLESPIE MS, Chiang K, Regan-Mochrie GL, Choi SY, et al
    PRMT5-regulated splicing of DNA repair genes drives chemoresistance in breast cancer stem cells.
    Oncogene. 2024 Dec 18. doi: 10.1038/s41388-024-03264.
    PubMed     Abstract available


  38. TANG T, Yang T, Xue H, Liu X, et al
    Breast cancer stem cell-derived exosomal lnc-PDGFD induces fibroblast-niche formation and promotes lung metastasis.
    Oncogene. 2024 Dec 4. doi: 10.1038/s41388-024-03237.
    PubMed     Abstract available


    November 2024
  39. JAIN A, Barge A, Parris CN
    Combination strategies with PARP inhibitors in BRCA-mutated triple-negative breast cancer: overcoming resistance mechanisms.
    Oncogene. 2024 Nov 21. doi: 10.1038/s41388-024-03227.
    PubMed     Abstract available


  40. ESCOTO A, Hecksel R, Parkinson C, Crane S, et al
    Nuclear EGFR in breast cancer suppresses NK cell recruitment and cytotoxicity.
    Oncogene. 2024 Nov 9. doi: 10.1038/s41388-024-03211.
    PubMed     Abstract available


  41. NING W, Yang J, Ni R, Yin Q, et al
    Hypoxia induced cellular and exosomal RPPH1 promotes breast cancer angiogenesis and metastasis through stabilizing the IGF2BP2/FGFR2 axis.
    Oncogene. 2024 Nov 4. doi: 10.1038/s41388-024-03213.
    PubMed     Abstract available


    September 2024
  42. XIONG J, Zhou Z, Jiang Y, Li Q, et al
    Hypoxic stabilization of RIPOR3 mRNA via METTL3-mediated m(6)A methylation drives breast cancer progression and metastasis.
    Oncogene. 2024 Sep 28. doi: 10.1038/s41388-024-03180.
    PubMed     Abstract available


  43. ZHANG C, Lu YJ, Wang M, Chen B, et al
    Characterisation of APOBEC3B-Mediated RNA editing in breast cancer cells reveals regulatory roles of NEAT1 and MALAT1 lncRNAs.
    Oncogene. 2024 Sep 25. doi: 10.1038/s41388-024-03171.
    PubMed     Abstract available


  44. YOUSAFZAI NA, El Khalki L, Wang W, Szpendyk J, et al
    Kindlin-2 regulates the oncogenic activities of integrins and TGF-beta in triple-negative breast cancer progression and metastasis.
    Oncogene. 2024 Sep 19. doi: 10.1038/s41388-024-03166.
    PubMed     Abstract available


  45. ZHAO G, Zhang X, Meng L, Dong K, et al
    Single-cell RNA-sequencing reveals a unique landscape of the tumor microenvironment in obesity-associated breast cancer.
    Oncogene. 2024 Sep 16. doi: 10.1038/s41388-024-03161.
    PubMed     Abstract available


  46. FERNANDO W, Cruickshank BM, Arun RP, MacLean MR, et al
    ALDH1A3 is the switch that determines the balance of ALDH(+) and CD24(-)CD44(+) cancer stem cells, EMT-MET, and glucose metabolism in breast cancer.
    Oncogene. 2024 Sep 9. doi: 10.1038/s41388-024-03156.
    PubMed     Abstract available


  47. GRASSET EM, Deshpande A, Lee JW, Cho Y, et al
    Mapping the breast tumor microenvironment: proximity analysis reveals spatial relationships between macrophage subtypes and metastasis-initiating cancer cells.
    Oncogene. 2024;43:2927-2937.
    PubMed     Abstract available


    August 2024
  48. KONG Y, Lan T, Wang L, Gong C, et al
    BRD4-specific PROTAC inhibits basal-like breast cancer partially through downregulating KLF5 expression.
    Oncogene. 2024 Aug 20. doi: 10.1038/s41388-024-03121.
    PubMed     Abstract available


  49. YU S, Wu R, Si Y, Fan Z, et al
    Alternative splicing of ALDOA confers tamoxifen resistance in breast cancer.
    Oncogene. 2024 Aug 20. doi: 10.1038/s41388-024-03134.
    PubMed     Abstract available


  50. CORBIN J, Yu X, Jin J, Cai L, et al
    EZH2 PROTACs target EZH2- and FOXM1-associated oncogenic nodes, suppressing breast cancer cell growth.
    Oncogene. 2024 Aug 7. doi: 10.1038/s41388-024-03119.
    PubMed     Abstract available


    July 2024
  51. LESLIE TK, Tripp A, James AD, Fraser SP, et al
    A novel Na(v)1.5-dependent feedback mechanism driving glycolytic acidification in breast cancer metastasis.
    Oncogene. 2024 Jul 25. doi: 10.1038/s41388-024-03098.
    PubMed     Abstract available


  52. HAN X, Ren C, Lu C, Jiang A, et al
    Phosphorylation of USP27X by PIM2 promotes glycolysis and breast cancer progression via deubiquitylation of MYC.
    Oncogene. 2024 Jul 5. doi: 10.1038/s41388-024-03097.
    PubMed     Abstract available


    June 2024
  53. CASCIO S, Bartella V, Auriemma A, Johannes GJ, et al
    Retraction Note: Mechanism of leptin expression in breast cancer cells: role of hypoxia-inducible factor-1alpha.
    Oncogene. 2024 Jun 20. doi: 10.1038/s41388-024-03087.
    PubMed    


  54. SIRKISOON SR, Carpenter RL, Rimkus T, Anderson A, et al
    Correction: Interaction between STAT3 and GLI1/tGLI1 oncogenic transcription factors promotes the aggressiveness of triple-negative breast cancers and HER2-enriched breast cancer.
    Oncogene. 2024 Jun 12. doi: 10.1038/s41388-024-03084.
    PubMed    


  55. LEE SG, Woo SM, Seo SU, Lee HS, et al
    Non-canonical deubiquitination of OTUB1 induces IFNgamma-mediated cell cycle arrest via regulation of p27 stability.
    Oncogene. 2024;43:1852-1860.
    PubMed     Abstract available


    May 2024
  56. DORE S, Ali M, Sorin M, McDowell SAC, et al
    Exploring the prognostic significance of arm-level copy number alterations in triple-negative breast cancer.
    Oncogene. 2024 May 14. doi: 10.1038/s41388-024-03051.
    PubMed     Abstract available


  57. DAS C, Bhattacharya A, Adhikari S, Mondal A, et al
    A prismatic view of the epigenetic-metabolic regulatory axis in breast cancer therapy resistance.
    Oncogene. 2024 May 8. doi: 10.1038/s41388-024-03054.
    PubMed     Abstract available


  58. MA J, Chen Y, Li T, Cao Y, et al
    Suppression of lysosome metabolism-meditated GARP/TGF-beta1 complexes specifically depletes regulatory T cells to inhibit breast cancer metastasis.
    Oncogene. 2024 May 2. doi: 10.1038/s41388-024-03043.
    PubMed     Abstract available


  59. LAISNE M, Rodgers B, Benlamara S, Wicinski J, et al
    A novel bioinformatic approach reveals cooperation between Cancer/Testis genes in basal-like breast tumors.
    Oncogene. 2024;43:1369-1385.
    PubMed     Abstract available


    April 2024
  60. DOHENY D, Sirkisoon S, Carpenter RL, Aguayo NR, et al
    Correction: Combined inhibition of JAK2-STAT3 and SMO-GLI1/tGLI1 pathways suppresses breast cancer stem cells, tumor growth, and metastasis.
    Oncogene. 2024 Apr 27. doi: 10.1038/s41388-024-03046.
    PubMed    


  61. ZHOU Z, Zheng X, Zhao J, Yuan A, et al
    ULK1-dependent phosphorylation of PKM2 antagonizes O-GlcNAcylation and regulates the Warburg effect in breast cancer.
    Oncogene. 2024 Apr 17. doi: 10.1038/s41388-024-03035.
    PubMed     Abstract available


  62. CHEN X, Ma C, Li Y, Liang Y, et al
    COL5A1 promotes triple-negative breast cancer progression by activating tumor cell-macrophage crosstalk.
    Oncogene. 2024 Apr 12. doi: 10.1038/s41388-024-03030.
    PubMed     Abstract available


  63. BOTTONI L, Minetti A, Realini G, Pio E, et al
    NRF2 activation by cysteine as a survival mechanism for triple-negative breast cancer cells.
    Oncogene. 2024 Apr 10. doi: 10.1038/s41388-024-03025.
    PubMed     Abstract available


  64. RUSSO GC, Crawford AJ, Clark D, Cui J, et al
    Correction: E-cadherin interacts with EGFR resulting in hyper-activation of ERK in multiple models of breast cancer.
    Oncogene. 2024 Apr 5. doi: 10.1038/s41388-024-03023.
    PubMed    


    March 2024
  65. RUSSO GC, Crawford AJ, Clark D, Cui J, et al
    E-cadherin interacts with EGFR resulting in hyper-activation of ERK in multiple models of breast cancer.
    Oncogene. 2024 Mar 20. doi: 10.1038/s41388-024-03007.
    PubMed     Abstract available


  66. MCCLELLAN B, Wilson CN, Brenner AJ, Jolly CA, et al
    Flotillin-1 palmitoylation is essential for its stability and subsequent tumor promoting capabilities.
    Oncogene. 2024;43:1063-1074.
    PubMed     Abstract available


    February 2024
  67. PRADEEP C-, Zeisel A, Kostler WJ, Lauriola M, et al
    Correction: Modeling invasive breast cancer: growth factors propel progression of HER2-positive premalignant lesions.
    Oncogene. 2024 Feb 28. doi: 10.1038/s41388-024-02990.
    PubMed    


  68. YANG L, Wang M, Wang Y, Zhu Y, et al
    LINC00460-FUS-MYC feedback loop drives breast cancer metastasis and doxorubicin resistance.
    Oncogene. 2024 Feb 28. doi: 10.1038/s41388-024-02972.
    PubMed     Abstract available


  69. ZHENG XQ, Guo JP, Yang H, Kanai M, et al
    Retraction Note: Aurora-A is a determinant of tamoxifen sensitivity through phosphorylation of ERalpha in breast cancer.
    Oncogene. 2024 Feb 23. doi: 10.1038/s41388-024-02983.
    PubMed    


  70. BARRA J, Crosbourne I, Roberge CL, Bossardi-Ramos R, et al
    DMT1-dependent endosome-mitochondria interactions regulate mitochondrial iron translocation and metastatic outgrowth.
    Oncogene. 2024;43:650-667.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.